Indeed, a number of animal studies have supported the hypothesis that increasing ratios of EETs to DHETs through genetic deletion or pharmacological inhibition of sEH offers protection against experimental cerebral ischemia [15, 16], parkinsonism [17], and seizures [18]. The gene discussed is EPHX2; the disease is Parkinsonism.